• Combining multiple novel therapies for secondary prevention may lower event risk in ASCVD

    1 month ago - By Healio

    The combination of icosapent ethyl, ezetimibe and rivaroxaban may lower risk for CV death, MI and stroke well beyond the treatment effect of secondary prevention with background medical therapy for atherosclerotic CVD, a speaker reported.
    “Aspirin and high-intensity statin therapies are recommended for secondary prevention of ASCVD,” Robert W. Ariss, a fourth-year medical student at the University of Toledo College of Medicine and Life Sciences, said during a presentation at the virtual American Society for Preventive Cardiology Congress on CVD Prevention. “However, despite
    Read more ...